List of Lazanda drug patents
Lazanda is owned by Btcp Pharma.
Lazanda contains Fentanyl Citrate.
Lazanda has a total of 5 drug patents out of which 0 drug patents have expired.
Lazanda was authorised for market use on 30 June, 2011.
Lazanda is available in spray, metered;nasal dosage forms.
Lazanda can be used as management of breakthrough pain in patients with cancer.
The generics of Lazanda are possible to be released after 26 January, 2032.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9078814 | BTCP PHARMA | Intranasal spray device containing pharmaceutical composition |
Jan, 2024
(7 months from now) | |
| US9814705 | BTCP PHARMA | Intranasal spray device containing pharmaceutical composition |
Jan, 2024
(7 months from now) | |
| US8889176 | BTCP PHARMA | Method of managing or treating pain |
Jan, 2024
(7 months from now) | |
| US8216604 | BTCP PHARMA | Method of managing or treating pain |
Oct, 2024
(1 year, 4 months from now) | |
| US9731869 | BTCP PHARMA | Container |
Jan, 2032
(8 years from now) | |
Drugs and Companies using FENTANYL CITRATE ingredient
Market Authorisation Date: 30 June, 2011
Treatment: Management of breakthrough pain in patients with cancer
Dosage: SPRAY, METERED;NASAL
LAZANDA family patents
6
United States
4
Korea, Republic of
4
European Union
3
Spain
3
Portugal
3
United Kingdom
2
Hong Kong
2
Denmark
2
Poland
2
China
2
Brazil
2
Canada
2
Japan
2
New Zealand
2
Cyprus
2
Slovenia
2
Mexico
2
Australia
2
South Africa
1
RS
1
Ukraine
1
EA
1
Norway
1
Croatia
1
San Marino
1
Israel
1
Taiwan
1
Georgia
1
Lithuania
1
Hungary
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic